



# Raffles Medical Group Ltd and its Subsidiaries

Annual Report For The Year Ended 31 December 2002

13	Corporate Governance
31	Directors' Report
39	Statement by Directors
40	Auditors' Report
41	Balance Sheet
42	Profit and Loss Accounts
43	Consolidated Statement of Changes in Equity
44	Statement of Changes in Equity
45	Consolidated Statement of Cash Flows
47	Notes to the Financial Statements
75	Additional Information
76	Shareholdings Statistics
77	Notice of Annual General Meeting
79	Proxy Form

# Corporate Governance

## Corporate Governance Statement

The Directors and Management of Raffles Medical Group are committed to comply with the Code of Corporate Governance (Code) issued by the Corporate Governance Committee in March 2001 so as to ensure greater transparency and protection of shareholders' interests. This statement outlines the main corporate governance practices that were in place throughout the financial year. The Company has generally complied with the principles of the Code.

## The Board's Conduct of its Affairs

RMG's Board of Directors (the Board) primary role is to protect and enhance long-term value of all RMG's shareholders. It sets the overall strategy for the Group and supervises senior management. To fulfil this role, the Board is responsible for the overall corporate governance of the Group including setting its strategic direction, establishing goals for management and monitoring the achievement of these goals.

The Board currently holds 4 scheduled meetings each year. In addition, the Directors meet to discuss strategy and hold extraordinary meetings at such other times as may be necessary to address any specific significant matters that may arise.

We have disclosed the attendance of the Directors at Board Meetings and Board Committees, as well as the frequency of such meetings in the Report.

The Board has decided that certain matters must always be approved by the Board. These include:

- approval of quarterly results announcements;
- approval of the annual report and accounts;
- declaration of interim dividends and proposal of final dividends;
- convening of shareholders' meetings;
- approval of corporate strategy and direction of the Group;
- material acquisition or disposal;
- approval of transactions involving a conflict of interest for a substantial shareholder or a director or interested person transactions; and
- appointment of new directors

All other matters are delegated to Committees whose actions are reported to and monitored by the Board.

## Training of Directors

All new Directors are given briefing sessions on the operations of all the key business and support units. Prior to their appointment, new directors are provided with relevant information on their duties as directors under Singapore law. Directors are also updated regularly on accounting and regulatory changes.

Directors may at any time request further explanation, briefing or informal discussion on any aspects of the company operations.

## Board Composition and Balance

The names of the directors of the Company in office at the date of this Statement are set out below.

The Board has reviewed its composition and is satisfied that such composition is appropriate. The Board constantly examines its size with a view to determine the impact upon its effectiveness.

As at the date of this report, RMG's Board comprises five suitably qualified members:

<b>Name of Directors</b>	<b>Date of appointment</b>	<b>Nature of appointment</b>	<b>Prime function</b>	<b>Other functions</b>	<b>Academic and professional</b>
Dr Loo Choon Yong Age: 55	16/8/89	Executive/Non Independent	Chairman	Chairman of Nomination & Compensation Committee and Member of Audit Committee	MBBS (S'pore), MCFP (S'pore), Dip. Cardiac Medicine (London), LLB (Hons) London, Barrister(Middle Temple)
Mr Tan Soo Nan Age: 56	28/07/00	Non executive/ Independent	Member	Chairman of Audit Committee	Bachelor of Business Admin (Hons), Associate of The Chartered Institute of Bankers  Chief Executive Officer of Singapore Pools (Pte) Ltd
Prof Lim Pin Age: 68	19/02/01	Non executive/ Independent	Member	Member of Nomination & Compensation Committee	MBBChir (Cambridge), MA (Cambridge), MRCP (London), MD (Cambridge), FAM, FRCP (London), FRACP, FRCPE, FACP  Professor of Medicine at NUS and Senior Consultant Endocrinologist at NUH
Asoc Prof Wee Beng Geok Age: 56	27/11/00	Non executive/ Independent	Member	Member of Audit Committee and Nomination & Compensation Committee	Phd (Management Systems & Sciences) MBA Cranfield University (UK)  Associate Professor at Nanyang Business School, Nanyang Technological University
Dr David Lawrence Age: 64	25/07/97	Non executive/ Independent	Member	-	BA degree (Amherst College), MD (University of Kentucky), MPH (University of Washington)

Particulars of interests of directors who held office at the end of the financial year in shares, debentures, warrants and share options in the Company and in related corporations (other than wholly-owned subsidiaries) are set out in the Directors' Report.

### **Independent Members of the Board**

Four of the 5 members of the Board are Independent Directors. They are: Dr David Lawrence, Mr Tan Soo Nan, Prof Lim Pin and Assoc Prof Wee Beng Geok. The criterion of independence is based on the definition given in the Code. The Board considers an “independent” director as one who has no relationship with the Company, its related companies or its officers that could interfere, or be reasonably perceived to interfere, with the exercise of the director’s independent business judgment.

As non-executive members of the Board, the Independent Directors, exercise no management functions in the Company or any of its subsidiaries. Although all the Directors have equal responsibility for the performance of the Group, the role of the non-executive directors is particularly important in ensuring that the strategies proposed by the executive management are fully discussed and rigorously examined and take account of the long-term interests, not only of the shareholders, but also of employees, customers, suppliers and the many communities in which the Group conducts business.

The Board considers its non-executive directors to be of sufficient calibre and number and their views to be of sufficient weight that no individual or small group can dominate the Board’s decision-making processes. The non-executive directors have no financial or contractual interests in the Group other than by way of their fees, shareholdings and participation in the Group Stock Option as set out in the Directors’ Report.

The Company’s Articles of Association, require all directors to submit themselves for re-election at least once every three years at the Company’s Annual General Meeting.

### **Chairman and Chief Executive Officer (Executive Chairman)**

It is the view of the Board that it is in the best interests of the Group to adopt a single leadership structure ie where the CEO and Chairman of the Board is the same person, so as to ensure that the decision-making process of the Group would not be unnecessarily hindered.

The Executive Chairman is Dr Loo Choon Yong who is responsible for the day-to-day running of the Group as well as the exercise of control over the quality, quantity and timelines of information flow between management and the Board. He has played an instrumental role in developing the business of the Group and has also provided the Group with vision and strong leadership.

All major decisions by the Executive Chairman are reviewed by the Audit Committee. His performance and remuneration is reviewed periodically by the Nomination & Compensation Committee. Both the Audit and Nomination & Compensation Committees comprise mainly of Independent Directors of the Group. As such the Board believes that there are adequate safeguards in place against having a concentration of power and authority in a single individual.

### **Criteria for Board Membership**

Board Members are selected for their character, judgment, business experience and acumen. Where a director has multiple board representations, the Nomination & Compensation Committee will evaluate whether or not a director is able to and has been adequately carrying out his or her duties as director of the Company. Final approval of a candidate is determined by the full Board.

In appointing directors, RMG Board considers the range of skills and experience required in the light of:

- the geographical spread and diversity of the Group’s businesses;
- the strategic direction and progress of the Group;
- the current composition of the Board; and
- the need for independence

### Board Performance

Informal reviews of the Board's collective performance are conducted periodically and on a regular basis by the Nomination and Compensation Committee, with inputs from the other Directors and the Executive Chairman. Such performance criteria includes comparisons with its industry peers. The Board considers that it would be more appropriate in the first phase of its appraisal process to focus on collective Board performance and defer individual assessment to a later stage.

The Board is also of the view that the financial indicators set out in the Code as guides for the evaluation of Directors are more of a measure of Management's performance and less applicable to Directors. The Board therefore believes that its performance should be judged on the basis of accountability as a whole, rather than strict definitive financial performance criteria.

### Access of Information

Directors receive a regular supply of information from management about the Group so that they are equipped to play as full a part as possible in Board meetings. Detailed Board papers are prepared for each meeting of the Board. The Board papers include sufficient information from management on financial, business and corporate issues to enable the Directors to be properly briefed on issues to be considered at Board meetings.

All Directors have unrestricted access to the Company's records and information and receive detailed financial and operational reports from senior management during the year to enable them to carry out their duties. Directors also liaise with senior management as required, and may consult with other employees and seek additional information on request.

In addition, Directors have separate and independent access to the advice and services of the Company Secretary, who is responsible to the Board for ensuring the established procedures and relevant statutes and regulations are complied with. The Company Secretary attends all Board meetings.

Each director has the right to seek independent legal and other professional advice, at the Company's expense, concerning any aspect of the Group's operations or undertakings in order to fulfil their duties and responsibilities as directors.

### Remuneration Matters

The Group's remuneration policy is to provide compensation packages at market rates which reward successful performance and attract, retain and motivate managers and directors.

The Nomination & Compensation Committee determines the remuneration packages for the Executive Chairman and senior management based on the performance of the Group and the individual. The Executive Chairman does not participate in meetings to discuss his compensation package. The performance of non-executive Directors is reviewed by the Executive Chairman on an ongoing basis.

Details of remuneration paid to the directors are set out below:

Remuneration band	Number of directors	
	2003	2002
S\$500,000 and above	1	1
S\$250,000 to below S\$500,000	-	-
Below S\$250,000	4	4
	5	5

Summary compensation table for the year ended 31 December 2003 (Group):

Name of Directors	Salary(1) %	Bonus(2) %	Directors' fees %	Total Compensation %	Share Options Grants(3)	Exercise Price	Date of Expiry
<b>\$500,000 and above</b>							
Dr Loo Choon Yong Executive Chairman	34	66	-	100	-	-	-
<b>Below \$250,000</b>							
Dr David Lawrence Non-executive	-	-	100	100	200,000	\$0.285	31/3/08
Mr Tan Soo Nan Non-executive	-	-	100	100	200,000	\$0.285	31/3/08
Assoc Prof Wee Beng Geok Non-executive	-	-	100	100	200,000	\$0.285	31/3/08
Prof Lim Pin Non-executive	-	-	100	100	200,000	\$0.285	31/3/08

(1) The salary amount shown is inclusive of allowances, CPF, all fees other than directors' fees, and other emoluments.

(2) The bonus amount shown is inclusive of CPF.

(3) Relates to options granted during the year by the Company.

### Key Executives' Remuneration

The Code requires the remuneration of at least the top 5 key executives who are not also directors to be disclosed within bands of S\$250,000. The Company believes that disclosure of the remuneration of individual executives who may also be clinicians is disadvantageous to its business interests, given the highly competitive industry conditions, where poaching of executives has become commonplace in a liberalised environment.

### Accountability and Audit

In presenting the annual financial statements and quarterly announcement to shareholders, the Board aims to provide shareholders with a balanced and comprehensive assessment of the Group's position and prospects. Management currently provides the Board with appropriately detail and management accounts of the Group's performance, position and prospects on a quarterly basis.

## Board Committees

To assist the Board in the execution of its duties, the Board has delegated specific functions to the following committees:

- (a) Nomination & Compensation Committee
- (b) Audit Committee

### Nomination & Compensation Committee

This committee was established in July 2001 and comprises the Executive Chairman, Dr Loo Choon Yong and two independent directors – Prof Lim Pin and Associate Professor Wee Beng Geok. The Committee, in consultation with the Chairman is responsible for the implementation and administration of the Employee Share Option Scheme as well as reviewing the appointment and compensation of senior management staff. Members of the Committee who are eligible are not involved in deliberations in respect to any options to be granted to them. The Executive Chairman of the Group opted not to participate in the Employee Share Option Scheme. The Committee also reviewed the compensation of the Executive Chairman to ensure that he is appropriately rewarded, giving due regard to the financial and commercial health and business needs of the Group.

### Audit Committee

The Audit Committee, chaired by Mr Tan Soo Nan, an Independent Director, meets periodically with the Group's external auditors and its senior management to review accounting, auditing and financial reporting matters so as to ensure that an effective control environment is maintained in the Group.

The Audit Committee also monitors proposed changes in accounting policies and discusses the accounting implications of major transactions. In addition, the Committee advises the Board regarding the adequacy of the Group's internal controls and the contents and presentation of its preliminary, interim and annual reports.

Specifically, the Audit Committee:

- reviews the audit plans and scope of audit examination of the external auditors;
- evaluates the overall effectiveness of the external audits through regular meetings with each group of auditors;
- determines that no restrictions are being placed by management upon the work of the external auditors;
- evaluates the adequacy of the internal control systems of the Group by reviewing written reports from the external auditors, and management's responses and actions to correct any deficiencies;
- evaluates adherence to the Group's administrative, operating and internal accounting controls;
- reviews the annual and interim financial statements and announcements to shareholders before submission to the Board for adoption
- reviews interested person transactions (as defined in Chapter 9 of the Listing Manual of the Singapore Exchange Securities Trading Limited ("SGX-ST")) to ensure that they are on normal commercial terms and not prejudicial to the interests of the Company or its shareholders;
- discusses with the external auditors any suspected fraud or irregularity or failure of internal controls or suspected infringement of any Singapore or other applicable law, rule and regulation; and
- considers other matter as requested by the Board.

The Audit Committee is authorised to investigate any matter within its terms of reference, and has full access to management and also full discretion to invite any director or executive officer to attend its meetings, as well as reasonable resources to enable it to discharge its function properly.

### Internal Controls

The Board acknowledges that it is responsible for the overall internal control framework. It recognises that no internal control system is foolproof as the system is designed to manage rather than eliminate the risk of failure to achieve business objectives. It can therefore provide only reasonable and not absolute assurance against material misstatement or loss. The Directors regularly review the effectiveness of all internal controls, including operational controls.

The Board assess risks and evaluates them as part of an integral part of the annual strategic planning cycle. Having identified the risks to achievement of their strategic objectives, each business unit in the Company is required to document the management and mitigating actions in place and proposed in respect of each significant risk.

### Internal Audit

The Group set up an in-house internal audit function during the year. The internal audit unit will promote internal control in the Group and monitor the performance and application of internal procedures. The internal auditor is expected to meet or exceed the standards set by nationally or internationally recognised professional bodies including the Standards for the Professional Practice of Internal Auditing set by The Institute of Internal Auditors.

The internal audit unit will also assess the risks affecting the Group in its activities and in all its entities so that they can be identified, analysed and sufficiently hedged.

The Group's internal audit function has a formal charter approved by the Board in early 2004 which describes its purpose, authority and responsibility. It supports the Directors in assessing key internal controls through a structured review programme.

The internal auditor reports primarily to the Chairman of the Audit Committee, Mr Tan Soo Nan. The Audit Committee will ensure that the internal auditor has adequate resources and has appropriate standing within the Group. The Committee will assess the effectiveness of the internal auditor on an annual basis by examining:

- the scope of the internal auditors' work;
- the quality of their reports;
- their relationship with the external auditors; and
- their independence of the areas reviewed.

### Communication with Shareholders

In line with continuous disclosure obligations of the Company, pursuant to the SGX-ST's Listing Rules and the Singapore Companies Act, the Board's policy is that RMG shareholders are informed of all major developments that impact the Group.

Information is communicated to shareholders on a timely basis. Where there is inadvertent disclosure made to a selected group, the Company will make the same disclosure publicly as soon as practicable. Communication is made through:

- annual reports that are prepared and issued to all shareholders. The Board makes every effort to ensure that the annual report includes all relevant information about the Group, including future developments and other disclosures required by the Companies Act and Singapore Statements of Accounting Standard.
- financial statements containing a summary of the financial information and affairs of the Group for the period;
- notices of and explanatory memoranda for annual general meetings and extraordinary general meetings;
- press and analyst briefings for the Group's quarterly and annual results as well as other briefings, as appropriate;

### Communication with Shareholders (cont'd)\

- press releases on major developments of the Group;
- disclosures to the SGX-ST; and
- the Group's website at <http://www.rafflesmedical.com> at which shareholders can access information on the Group. The website provides, inter alia, corporate announcements, press releases, annual reports, and a profile of the Group.

In addition, shareholders are encouraged to attend the AGM to ensure a high level of accountability and to stay informed of the Group's strategy and goals. The AGM is the principal forum for dialogue with shareholders.

The notice of the AGM is despatched to shareholder, together with explanatory notes or a circular on items of special business, at least 14 working days before the meeting. The Board welcomes questions from shareholders who have an opportunity to raise issues either informally or formally before or at the AGM. The Chairmen of the Audit and the Nomination & Compensation Committees are normally available at the meeting to answer those questions relating to the work of these Committees.

Each item of special business included in the notice of the meeting is accompanied, where appropriate, by an explanation for the proposed resolution. Separate resolutions are proposed for substantially separate issues at the meeting.

The Company counts all proxy votes and the Chairman will inform shareholders of the level of the proxies lodged on each resolution. The votes for and against each resolution are given following the show of hands for that resolution.

### Attendance at Board and Board Committee Meetings

The table below sets the attendances at meetings of the Board and Board Committees convened in the course of the year under review:

Name of Directors	Board		Audit Committee		Nomination & Compensation	
	No. of meetings held	No. of meetings attended	No. of meetings held	No. of meetings attended	No. of meetings held	No. of meetings attended
Dr Loo Choon Yong	5	5	4	4	1	1
Mr Tan Soo Nan	5	5	4	4	-	-
Assoc Prof Wee Beng Geok	5	5	4	4	1	1
Dr David Lawrence	5	5	-	-	-	-
Prof Lim Pin	5	5	-	-	1	1

## Directors' Report

### Directors' Report

We are pleased to submit this annual report to the members of the Company together with the audited financial statements for the financial year ended 31 December 2003.

### Directors

The directors in office at the date of this report are as follows:-

Dr Loo Choon Yong  
 Dr David M. Lawrence  
 Prof Lim Pin  
 Mr Tan Soo Nan  
 Assoc Prof Wee Beng Geok

### Directors' Interests

According to the register kept by the Company for the purposes of Section 164 of the Companies Act, Chapter 50 (the "Act"), particulars of interests of directors who held office at the end of the financial year in shares, debentures, warrants and share options in the Company and in a related corporation are as follows:-

The Company	Holdings in the name of the director, spouse or infant children		Other holdings in which the director is deemed to have an interest	
	At beginning of the year	At end of the year	At beginning of the year	At end of the year
	Ordinary shares of \$0.10 each			
Dr Loo Choon Yong	50,841,999	34,841,999	206,157,000	222,157,000
Dr David M. Lawrence	256,000	256,000	-	-
Mr Tan Soo Nan	30,000	50,000	-	-
Assoc Prof Wee Beng Geok	30,000	30,000	-	-
	Options to subscribe for ordinary shares of \$0.10 each			
The Company	At beginning of the year	At end of the year	At beginning of the year	At end of the year
Dr David M. Lawrence	250,000	250,000	\$0.430	15/2/2001
	200,000	200,000	\$0.330	8/4/2002
	-	200,000	\$0.285	31/3/2003
Prof Lim Pin	220,000	220,000	\$0.330	8/4/2002
	-	200,000	\$0.285	31/3/2003
Mr Tan Soo Nan	150,000	150,000	\$0.430	15/2/2001
	250,000	250,000	\$0.330	8/4/2002
	-	200,000	\$0.285	31/3/2003
Assoc Prof Wee Beng Geok	100,000	100,000	\$0.430	15/2/2001
	250,000	250,000	\$0.330	8/4/2002
	-	200,000	\$0.285	31/3/2003

**Directors' Interests (cont'd)**

Immediate Holding Company	Holdings in the name of the director, spouse or infant children		Other holdings in which the director is deemed to have an interest	
	At beginning of the year	At end of the year	At beginning of the year	At end of the year
Raffles Medical Holdings Pte Ltd		Ordinary shares of \$0.10 each		
Dr Loo Choon Yong	100,000	100,000	-	-

The options in the Company are exercisable as follows:

- (i) the options granted in 2001 are exercisable during a period commencing 12 months from the Date of Grant for up to 200,000 shares and 24 months from the Date of Grant for the balance and expires at the end of 60 months from the Date of Grant.
- (ii) the options granted in 2002 are exercisable during a period commencing 12 months from the Date of Grant for the first 100,000 shares, 24 months from the Date of Grant for the next 100,000 shares and the balance after 36 months and expires at the end of 60 months from the Date of Grant.
- (iii) the options granted in 2003 are exercisable during a period commencing 12 months from the Date of Grant for the first 100,000 shares, 24 months from the Date of Grant for the next 100,000 shares and the balance after 36 months and expires at the end of 60 months from the Date of Grant.

By virtue of Section 7 of the Act, Dr Loo Choon Yong is deemed to have an interest in all of the wholly-owned subsidiaries of Raffles Medical Group Ltd at the beginning and at the end of the financial year.

Except as disclosed in this report, no director who held office at the end of the financial year had interests in shares, debentures, warrants or share options of the Company or of related corporations either at the beginning of the financial year, or at the end of the financial year.

There was no change in any of the abovementioned interests in the Company and related corporations between the end of the financial year and 21 January 2004.

Except as disclosed under the "Share Options" section of this report, neither at the end of nor at any time during the financial year was the Company a party to any arrangement whose objects are, or one of whose objects is, to enable the directors of the Company to acquire benefits by means of the acquisition of shares, debentures, warrants or share options of the Company or any other body corporate.

Except as disclosed in the accompanying financial statements, since the end of the last financial year, no director has received or become entitled to receive a benefit by reason of a contract made by the Company or a related corporation with the director or with a firm of which he is a member or with a company in which he has a substantial financial interest.

## Share Options

### *Employees' Share Option Scheme*

- (1) The Raffles Medical Group Employees' Share Option Scheme ("RMG 1997 Scheme") for the Company was terminated on 31 October 2000. Details of the RMG 1997 Scheme were set out in the Directors' Report for the financial year ended 31 December 1998. The termination of the RMG 1997 Scheme will not affect the subscription rights comprised in options granted pursuant to the RMG 1997 Scheme prior to the termination. Such options will continue to be exercisable in accordance with the rules of the RMG 1997 Scheme. However, no further options will be granted under this scheme.
- (2) On 31 October 2000, the shareholders of the Company approved the Raffles Medical Group (2000) Share Option Scheme ("RMG 2000 Scheme") at the Extraordinary General Meeting. Details of the RMG 2000 Scheme were set out in the Directors' Report for the financial year ended 31 December 2000.
- (3) Both the RMG 1997 Scheme (in respect of the administration of any exercise of options already granted thereafter prior to its termination in October 2000) and the RMG 2000 Scheme are administered by the Nomination and Compensation Committee ("Committee") comprising the following directors:-

Dr Loo Choon Yong  
 Prof Lim Pin  
 Assoc Prof Wee Beng Geok

Dr Loo Choon Yong is not participating in the schemes.

- (4) On 31 March 2003, additional options were granted pursuant to the RMG 2000 Scheme to subscribe for ordinary shares of \$0.10 each at an exercise price of \$0.285 as follows:-

	<b>Company</b>
Directors and Executive Directors of the Company and the subsidiaries	3,220,000
Full-time employees	6,658,000
	<b>\$9,878,000</b>

- (5) As at 31 December 2003, outstanding options to take up shares of \$0.10 each in the Company under the RMG 2000 Scheme were as follows:-

Date of Grant	:	15 Feb 2001	8 April 2002	31 Mar 2003
Exercise Price	:	\$0.430	\$0.330	\$0.285
Expiry Date (for employees)	:	14 Feb 2011	7 April 2012	31 Mar 2013
Expiry Date (for non-employees)	:	14 Feb 2006	7 April 2007	31 Mar 2008
Outstanding Options as at 1/1/2003/ Date of grant	:	10,173,000	13,274,000	9,878,000
No. of Options Exercised	:	-	724,000	-
No. of Options Cancelled/Lapsed	:	1,267,000	858,000	835,000
Outstanding Options as at 31/12/2003	:	8,906,000	11,692,000	9,043,000

**Share Options (cont'd)***Employees' Share Option Scheme (cont'd)*

- (6) As at 31 December 2003, outstanding options to take up shares of \$0.10 each in the Company under the RMG 1997 Scheme were as follows:-

Date of Grant	:	9 March 2000
Exercise Price*	:	\$0.57
Expiry Date	:	8 March 2005
Outstanding Options as at 1/1/2003	:	5,400,600
No. of Options Exercised	:	-
No. of Options Cancelled/Lapsed	:	309,100
Outstanding Options as at 31/12/2003	:	5,091,500

\* Adjusted for the Rights Issue on 7 June 2000.

- (7) No options have been granted to controlling shareholders of the Company and their associated companies and parent group employees. No participant has received 5% or more of the total number of options available under the Schemes.
- (8) The following are details of options granted to Directors:-

Name of participant	Options granted during the financial year under review	Aggregate options granted since commencement of Scheme to end of the financial year under review	Aggregate options exercised since commencement of Scheme to end of the financial year under review	Aggregate options outstanding as at the end of the financial year under review
<i>Directors of the Company</i>				
Dr David M. Lawrence	200,000	650,000	-	650,000
Prof Lim Pin	200,000	420,000	-	420,000
Mr Tan Soo Nan	200,000	600,000	-	600,000
Assoc Prof Wee Beng Geok	200,000	550,000	-	550,000
<b>Total</b>	<u>800,000</u>	<u>2,220,000</u>	<u>-</u>	<u>2,220,000</u>

**Share Options (cont'd)***Employees' Share Option Scheme (cont'd)*

(9) Statutory information regarding the above options are as follows:-

(a) *RMG 1997 Scheme*

Options are exercisable during a period commencing 12 months from the date of grant of the options and expiring at the end of 60 months from the date of grant.

*RMG 2000 Scheme*

Options are exercisable in whole or in part:-

(i) in relation to shares for which the subscription price is determined on market value, a period commencing on such date in respect of such proportion of the option amount as the Committee may prescribe (but which shall in any event be no earlier than the date immediately after the first anniversary of the date of grant) and ending on the date immediately before the tenth anniversary of such date of grant for an employee and ending on the date immediately before the fifth anniversary of such date of grant for a non-employee; and

(ii) in relation to shares for which the subscription price is determined at a discount to market value, a period commencing on such date in respect of such proportion of the option amount as the Committee may prescribe (but which shall in any event be no earlier than the date immediately after the second anniversary of the date of grant) and ending on the date immediately before the tenth anniversary of such date of grant for an employee and ending on the date immediately before the fifth anniversary of such date of grant for a non-employee.

(b) The number of shares which may be acquired by a participant and the exercise price are subject to adjustment, as confirmed by the auditors of the Company that such adjustment is fair and reasonable, by reason of any issue of additional shares in the Company by way of rights or capitalisation of profits or reserves made which an option remains unexercised.

(10) Save as disclosed above, there were no unissued shares of the Company or its subsidiaries under option as at the end of the financial year.

(11) The options granted by the Company do not entitle the holders of the options, by virtue of such holdings, to any right to participate in any share issue of any other company.

**Audit Committee**

The members of the Audit Committee at the date of this report are as follows:-

Mr Tan Soo Nan (Chairman), non-executive director  
Dr Loo Choon Yong, executive director  
Assoc Prof Wee Beng Geok, non-executive director

The Audit Committee performs the functions specified by section 201B of the Act, and the Listing Manual and the Best Practices Guide of the Singapore Exchange.

**Audit Committee (cont'd)**

The Audit Committee held four meetings since the last directors' report. In performing its functions, the Audit Committee met with the Company's external auditors to discuss the scope of their work and the results of their examination and evaluation of the Company's internal accounting control system.

The Audit Committee also reviewed the following:-

- assistance provided by the Company's officers to the external auditors;
- financial statements of the Group and the Company prior to their submission to the directors of the Company for adoption; and
- interested person transactions (as defined in Chapter 9 of the Listing Manual of the Singapore Exchange).

The Audit Committee has full access to management and is given the resources required for it to discharge its functions. It has full authority and discretion to invite any director or executive officer to attend its meetings.

The Audit Committee is satisfied with the independence and objectivity of the external auditors and has recommended to the Board of Directors that the auditors, KPMG, be nominated for re-appointment as auditors at the forthcoming Annual General Meeting of the Company.

**Auditors**

The auditors, KPMG, have indicated their willingness to accept re-appointment.

On behalf of the Board of Directors

.....  
DR LOO CHOON YONG  
Director

.....  
MR TAN SOO NAN  
Director  
Singapore

28 February 2004

## Statement by Directors

In our opinion:-

- (a) the financial statements set out on pages XX to XX are drawn up so as to give a true and fair view of the state of affairs of the Group and of the Company as at 31 December 2003 and of the results and cash flows of the Group and changes in equity of the Group and of the Company for the year ended on that date; and
- (b) at the date of this statement, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they fall due.

The Board of Directors has, on the date of this statement, authorised these financial statements for issue.

On behalf of the Board of Directors

.....  
DR LOO CHOON YONG  
Director

.....  
MR TAN SOO NAN  
Director

Singapore

28 February 2004

# Auditors' Report

## Report of the Auditors to the Members of Raffles Medical Group Ltd

We have audited the consolidated financial statements of the Group and the balance sheet and statement of changes in equity of the Company for the year ended 31 December 2003 as set out on pages XX to XX. These financial statements are the responsibility of the Company's directors. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with Singapore Standards on Auditing. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by the directors, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion:-

- (a) the consolidated financial statements of the Group and the balance sheet and statement of changes in equity of the Company are properly drawn up in accordance with the provisions of the Companies Act, Chapter 50 (the "Act") and Singapore Financial Reporting Standards to give a true and fair view of the state of affairs of the Group and of the Company as at 31 December 2003 and of the results, changes in equity and cash flows of the Group and of the changes in equity of the Company for the year ended on that date; and
- (b) the accounting and other records (excluding registers) required by the Act to be kept by the Company and by those subsidiaries incorporated in Singapore of which we are the auditors have been properly kept in accordance with the provisions of the Act.

We have considered the financial statements and auditors' reports of all the subsidiaries of which we have not acted as auditors, that have been included in the consolidated financial statements of the Group. The names of these subsidiaries are stated in note 4 to the financial statements.

We are satisfied that the financial statements of the subsidiaries that have been consolidated with the financial statements of the Company are in form and content appropriate and proper for the purposes of the preparation of the consolidated financial statements of the Group and we have received satisfactory information and explanations as required by us for those purposes.

The auditors' reports on the financial statements of the subsidiaries were not subject to any qualification and in respect of subsidiaries incorporated in Singapore did not include any comment made under Section 207(3) of the Act.

KPMG  
*Certified Public Accountants*

Singapore

28 February 2004

## Balance Sheet

as at 31 December 2003

	Note	Group		Company	
		2003 \$'000	2002 \$'000	2003 \$'000	2002 \$'000
<b>Non-current assets</b>					
Property, plant and equipment	3	22,283	24,049	2,742	3,153
Interest in subsidiaries	4	-	-	63,087	62,287
Interest in jointly controlled entities	5	50,585	49,595	-	-
Unquoted equity investment	6	-	-	-	-
Membership rights		88	88	68	68
Intangible assets	7	360	464	-	-
Deferred tax assets	8	1,806	2,024	-	-
		<u>75,122</u>	<u>76,220</u>	<u>65,897</u>	<u>65,508</u>
<b>Current assets</b>					
Investment in commercial notes	9	21,020	19,250	21,020	19,250
Inventories		2,837	2,236	1,125	1,174
Trade and other receivables	10	15,455	13,072	22,146	25,149
Cash and cash equivalents	13	11,311	8,930	10,030	7,867
		<u>50,623</u>	<u>43,488</u>	<u>54,321</u>	<u>53,440</u>
Less:					
<b>Current liabilities</b>					
Bank overdraft (unsecured)	13	662	172	-	-
Trade and other payables	14	20,109	17,767	11,366	9,688
Deferred income	17	160	595	105	539
Interest-bearing loans and borrowings (unsecured)	18	1,997	2,093	1,997	2,093
Employee benefits	19	3,055	2,560	1,688	1,317
Income tax payable		2,555	1,912	2,199	1,584
		<u>28,538</u>	<u>25,099</u>	<u>17,355</u>	<u>15,221</u>
<b>Net current assets</b>		<u>22,085</u>	<u>18,389</u>	<u>36,966</u>	<u>38,219</u>
		<u>97,207</u>	<u>94,609</u>	<u>102,863</u>	<u>103,727</u>
Less:					
<b>Non-current liabilities</b>					
Deferred tax liabilities	8	767	681	113	221
Minority interests		148	-	-	-
<b>Net Assets</b>		<u>96,292</u>	<u>93,928</u>	<u>102,750</u>	<u>103,506</u>
<b>Capital And Reserves</b>					
Share capital	20	38,734	38,662	38,734	38,662
Reserves	21	57,558	55,266	64,016	64,844
		<u>96,292</u>	<u>93,928</u>	<u>102,750</u>	<u>103,506</u>

The accompanying notes form an integral part of these financial statements.

## Consolidated Profit and Loss Accounts

Year ended 31 December 2003

	Note	2003 \$'000	Group 2002 \$'000
<b>Revenue</b>	22	99,105	87,997
Other income	23(a)	308	298
Inventories and consumables used	23(b)	(12,135)	(9,059)
Staff costs	23(c)	(56,748)	(50,000)
Depreciation of property, plant and equipment	3	(3,282)	(3,320)
Amortisation expense	7	(57)	(58)
Other operating expenses	23(d)	(17,312)	(19,583)
<b>Profit from operations</b>		9,879	6,275
Finance costs	23(f)	(91)	(93)
Share of profit/(loss) in a jointly controlled entity	5	420	(80)
<b>Profit from ordinary activities before taxation</b>		10,208	6,102
Income tax expense	24	(2,200)	(1,596)
<b>Profit from ordinary activities after taxation</b>		8,008	4,506
Minority interests		52	-
<b>Net profit for the year transferred to accumulated profits</b>		8,060	4,506
<b>Earnings per share expressed in cents</b>	25		
Basic		2.08	1.17
Diluted		2.07	1.17

*The accompanying notes form an integral part of these financial statements.*

## Consolidated Statement of Changes in Equity

Year ended 31 December 2003

Group	Share capital \$'000	Share premium \$'000	Exchange translation reserve \$'000	Accumulated profits \$'000	Total \$'000
<b>At 1 January 2002</b>	38,662	52,990	(592)	452	91,512
Exchange differences on translation of financial statements of overseas subsidiaries	-	-	323	-	323
Net profit for the year	-	-	-	4,506	4,506
Final dividend paid of 8% less tax at 22%	-	-	-	(2,413)	(2,413)
<b>At 31 December 2002</b>	38,662	52,990	(269)	2,545	93,928
At 1 January 2003	<u>38,662</u>	<u>52,990</u>	<u>(269)</u>	<u>2,545</u>	<u>93,928</u>
Issue of 724,000 shares of S\$0.10 each at a premium of S\$0.23 per share upon the exercise of options under Raffles Medical Group Employee's Share Option Scheme	72	167	-	-	239
Exchange differences on translation of financial statements of overseas subsidiaries	-	-	96	-	96
Net profit for the year	-	-	-	8,060	8,060
Dividend paid of 20% less tax at 22%	-	-	-	(6,031)	(6,031)
<b>At 31 December 2003</b>	<u>38,734</u>	<u>53,157</u>	<u>(173)</u>	<u>4,574</u>	<u>96,292</u>

*The accompanying notes form an integral part of these financial statements.*

Company	Share capital \$'000	Share premium \$'000	Accumulated profits \$'000	Total \$'000
<b>At 1 January 2002</b>	38,662	52,990	9,117	100,769
Net profit for the year	-	-	5,150	5,150
Final dividend paid of 8% less tax at 22%	-	-	(2,413)	(2,413)
<b>At 31 December 2002</b>	<u>38,662</u>	<u>52,990</u>	<u>11,854</u>	<u>103,506</u>
<b>At 1 January 2003</b>	38,662	52,990	11,854	103,506
Issue of 724,000 shares of \$0.10 each at a premium of \$0.23 per share upon the exercise of options under Raffles Medical Group Employees' Share Option Scheme	72	167	-	239
Net profit for the year	-	-	5,036	5,036
Dividend paid of 20% less tax at 22%	-	-	(6,031)	(6,031)
<b>At 31 December 2003</b>	<u>38,734</u>	<u>53,157</u>	<u>10,859</u>	<u>102,750</u>

*The accompanying notes form an integral part of these financial statements.*

# Consolidated Statement of Cash Flows

Year ended 31 December 2003

	Note	Company 2003 \$'000	2002 \$'000
<b>Operating activities</b>			
Profit from ordinary activities before taxation		10,208	6,102
Adjustments for:-			
Allowance for doubtful trade receivables		534	290
Amortisation of intangible assets		57	58
Deferred income recognised		(2,204)	(9,759)
Depreciation of property, plant and equipment		3,282	3,320
Finance costs		91	93
Foreign exchange loss		9	330
Interest income from fixed deposits and commercial notes		(308)	(298)
Loss on disposal of intangible assets		29	-
Property, plant and equipment written off		365	293
Share of results in a jointly controlled entity		(420)	80
		<hr/>	<hr/>
Operating profit before working capital changes		11,643	509
Changes in working capital:-			
Inventories		(603)	820
Trade and other receivables		(2,934)	1,631
Trade and other payables		2,841	3,030
		<hr/>	<hr/>
Cash generated from operations		10,947	5,990
Deferred income received		1,769	8,348
Dividend paid		(6,031)	(2,413)
Income tax paid		(1,823)	(1,486)
Interest paid		(91)	(93)
		<hr/>	<hr/>
<b>Cash flows from operating activities</b>		4,771	10,346
<b>Investing activities</b>			
Investment in commercial notes		(1,770)	(19,250)
Interest income received		321	242
Purchase of property, plant and equipment		(1,894)	(3,293)
Proceeds from sale of property, plant and equipment		4	-
Proceeds from sale of intangible assets		18	-
		<hr/>	<hr/>
<b>Cash flows from investing activities</b>		(3,321)	(22,301)
<b>Financing activities</b>			
Drawdown of term loan		-	2,093
Loan by minority interests		160	-
Proceeds from issue of shares		279	-
		<hr/>	<hr/>
<b>Cash flows from financing activities</b>		439	2,093
<b>Net Increase/(Decrease) in Cash and Cash Equivalents</b>		1,889	(9,862)
<b>Effect of Exchange Rate Changes on Cash and Cash Equivalents Held in Foreign Currency</b>		2	100
Cash and Cash Equivalents at beginning of the year		8,758	18,520
		<hr/>	<hr/>
<b>Cash and Cash Equivalents at end of the year</b>	13	10,649	8,758

The accompanying notes form an integral part of these financial statements.

# Notes to the Financial Statements

Year ended 31 December 2003

*These notes form an integral part of the financial statements.*

The financial statements were authorised for issue by the directors on 28 February 2004.

## 1. Domicile and Activities

Raffles Medical Group Ltd (the Company) is incorporated in the Republic of Singapore and has its registered office at 585, North Bridge Road, Raffles Hospital #11-00, Singapore 188770.

The principal activities of the Company are those relating to the operation of medical clinics and other general medical services. The Company is the sole proprietor of the following:-

Changi Medical Services  
 RafflesCare  
 Raffles Airport Medical Centre  
 Raffles Dental Surgery  
 Raffles Healthcare Consultancy  
 Raffles Health Screeners  
 Raffles Hospital  
 Raffles Labs  
 Raffles Medihelp  
 Raffles Optica  
 Raffles Pharmacare  
 Raffles Pharmacy

All transactions of these sole proprietorships are reflected in the financial statements of the Company. The principal activities of the subsidiaries are set out in Note 4 to the financial statements.

The immediate and ultimate holding company is Raffles Medical Holdings Pte Ltd, which is incorporated in Singapore.

The consolidated financial statements relate to the Company and its subsidiaries (referred to as the "Group") and the Group's interests in jointly controlled entities.

## 2. Summary of Significant Accounting Policies

### (a) Basis of Preparation

The financial statements are prepared in accordance with Singapore Financial Reporting Standards (FRS) including related Interpretations promulgated by the Council on Corporate Disclosure and Governance.

The financial statements were previously prepared in accordance with Singapore Statements of Accounting Standard (SAS). The transition from SAS to FRS has no effect on the financial statements of the Company and the Group.

The historical cost basis is used except that certain leasehold properties are stated at valuation and certain investments in debt securities are stated at market value. Amounts are expressed in Singapore dollars, unless stated otherwise.

## 2. Summary of Significant Accounting Policies (cont'd)

### (b) Measurement Currency

The measurement currency of the Company is the Singapore dollars. As sales and purchases are denominated primarily in Singapore dollars and receipts from operations are usually retained in Singapore dollars, the directors are of the opinion that the Singapore dollars reflects the economic substance of the underlying events and circumstances relevant to the Company.

### (c) Basis of Consolidation

#### (i) Subsidiaries

Subsidiaries are those companies controlled by the Company. Control exists when the Company has the power, directly or indirectly, to govern the financial and operating policies of a company so as to obtain benefits from its activities.

Investments in subsidiaries are stated in the Company's balance sheet at cost less impairment losses. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases.

#### (ii) Jointly Controlled Entities

Jointly controlled entities are those enterprises over whose activities the Group has joint control, established by contractual agreement.

Investments in jointly controlled entities are stated in the Company's balance sheet at cost, less impairment losses. In the Group's financial statements, they are accounted for by using the equity method of accounting.

### (d) Foreign Currencies

#### (i) Foreign Currency Transactions

Monetary assets and liabilities in foreign currencies, except where these are hedged by forward exchange contracts, are translated into Singapore dollars at rates of exchange approximate to those ruling at the balance sheet date. Transactions in foreign currencies are translated at rates ruling on transaction dates. Translation differences are included in the profit and loss account, except:

- Where foreign currency loans provide an effective hedge against the net investment in foreign subsidiaries, exchange differences arising on the loans are recognised directly in equity until disposal of the investment.
- Where monetary items in substance form part of the Group's net investment in the foreign subsidiaries, exchange differences arising on such monetary items are recognised directly in equity until disposal of the investments.

#### (ii) Foreign Operations

The assets and liabilities of foreign operations are translated to Singapore dollars at the rates of exchange ruling at the balance sheet date. The results of foreign operations are translated at the average exchange rates for the year. Exchange differences arising on translation are recognised directly in equity.

**2. Summary of Significant Accounting Policies (cont'd)**

**(e) Property, Plant and Equipment**

*(i) Owned Assets*

Property, plant and equipment are stated at cost less accumulated depreciation and impairment losses except for those land and buildings which are stated at their revalued amounts. The revalued amount is the fair value determined on the basis of existing use at the date of revaluation less any subsequent accumulated depreciation.

*(ii) Revaluation Reserve*

Revaluations are performed by independent professional valuers with sufficient regularity to ensure that the carrying amount of these assets does not differ materially from that which would be determined using fair values at the balance sheet date.

Any increase on revaluation is credited to revaluation reserve unless it offsets a previous decrease in value recognised in the profit and loss account. A decrease in value is recognised in the profit and loss account where it exceeds the increase previously recognised in the revaluation reserve.

*(iii) Disposal*

Upon disposal, any related revaluation surplus is transferred from the revaluation reserve to accumulated profits and is not taken into account in arriving at the gain or loss on disposal.

*(iv) Depreciation*

Depreciation is provided on a straight-line basis so as to write off items of property, plant and equipment, and major components that are accounted for separately over their estimated useful lives as follows:-

Leasehold properties	-	50 years
Medical equipment	-	8-10 years
Furniture and fittings	-	10 years
Office equipment	-	10 years
Motor vehicles	-	10 years
Computers	-	3 years
Renovations	-	6 years or over the remaining terms of relevant leases
Facilities equipment	-	10 years

**(f) Intangible Assets**

*(i) Assignment Fees*

Assignment fees relate to amounts paid to secure the tenancy of certain clinic premises. Assignment fees are stated at cost less accumulated amortisation and impairment losses. Assignment fees are amortised and recognised in the profit and loss account using a straight line method over its estimated useful life of 10 years.

*(ii) Goodwill*

Goodwill arising on acquisition represents the excess of the cost of acquisition over the fair value of the Group's share of the identifiable net assets acquired. Goodwill is stated at cost less accumulated amortisation and impairment losses. In respect of jointly controlled entities, the carrying amount of goodwill is included in the carrying amount of the investment in the jointly controlled entities. Goodwill is amortised from the date of initial recognition over its estimated useful life of 20 years.

**2. Summary of Significant Accounting Policies (cont'd)****(g) Inventories**

Inventories, comprising mainly pharmaceutical and medical supplies, are stated at the lower of cost and net realisable value. Cost is determined by applying the first-in first-out basis.

**(h) Cash and Cash Equivalents**

Cash and cash equivalents comprise cash balances and bank deposits. For the purpose of the statement of cash flows, cash and cash equivalents are presented net of bank overdrafts which are repayable on demand and which form an integral part of the Group's cash management.

**(i) Impairment**

The carrying amounts of the Group's assets are reviewed at each balance sheet to determine whether there is any indication of impairment. An impairment loss is recognised whenever the carrying amount of an asset exceeds its recoverable amount. The impairment loss is charged to the profit and loss account.

**(j) Employee Share Option**

No compensation cost or obligation is recognised when share options are issued under employee incentive programmes. When options are exercised, equity is increased by the amount of the proceeds received.

**(k) Deferred Income**

Fees collected in advance under the Managed Care Program are deferred. Such fees are recognised as income in the Profit and Loss Account on a straight-line basis over the contract period.

**(l) Liabilities and Interest-Bearing Borrowings**

Trade and other payables and interest-bearing borrowings are recognised at cost.

**(m) Deferred Tax**

Deferred tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Temporary differences are not recognised for goodwill not deductible for tax purposes and the initial recognition of assets or liabilities that affect neither accounting nor taxable profit. The amount of deferred tax provided is based on the expected manner of realisation or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the balance sheet date.

A deferred tax asset is recognised to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilised.

**(n) Revenue Recognition****Service Revenue**

Revenue is recognised upon the provision of healthcare and hospital services.

### 3. Property, Plant and Equipment

The Group	At Valuation ←					At Cost →				
	Leasehold properties \$'000	Leasehold properties \$'000	Medical equipment \$'000	Furniture and fittings \$'000	Office equipment \$'000	Motor vehicles \$'000	Computers \$'000	Renovations \$'000	equipment \$'000	Facilities Total \$'000
<b>Cost/Valuation</b>										
At 1 January 2003	3,860	5,169	13,750	2,839	879	501	3,038	2,912	1,665	34,613
Translation difference on consolidation	-	-	(7)	(2)	(4)	-	(2)	(4)	-	(19)
Additions	-	-	837	118	34	55	199	618	33	1,894
Disposals	-	-	(1,076)	(362)	(122)	(24)	(129)	(235)	-	(1,948)
At 31 December 2003	<u>3,860</u>	<u>5,169</u>	<u>13,504</u>	<u>2,593</u>	<u>787</u>	<u>532</u>	<u>3,106</u>	<u>3,291</u>	<u>1,698</u>	<u>34,540</u>
<b>Accumulated depreciation</b>										
At 1 January 2003	87	389	4,728	1,132	409	184	1,935	1,411	289	10,564
Translation difference on consolidation	-	-	(3)	-	(1)	-	(3)	(3)	-	(10)
Depreciation for the year	87	103	1,413	237	72	52	778	415	125	3,282
Disposals	-	-	(882)	(284)	(85)	(24)	(129)	(175)	-	(1,579)
At 31 December 2003	<u>174</u>	<u>492</u>	<u>5,256</u>	<u>1,085</u>	<u>395</u>	<u>212</u>	<u>2,581</u>	<u>1,648</u>	<u>414</u>	<u>12,257</u>
Depreciation charge for 2002	<u>87</u>	<u>103</u>	<u>1,415</u>	<u>253</u>	<u>83</u>	<u>40</u>	<u>782</u>	<u>401</u>	<u>156</u>	<u>3,320</u>
<b>Carrying amount</b>										
At 31 December 2003	<u>3,686</u>	<u>4,677</u>	<u>8,248</u>	<u>1,508</u>	<u>392</u>	<u>320</u>	<u>525</u>	<u>1,643</u>	<u>1,284</u>	<u>22,283</u>
At 31 December 2002	<u>3,773</u>	<u>4,780</u>	<u>9,022</u>	<u>1,707</u>	<u>470</u>	<u>317</u>	<u>1,103</u>	<u>1,501</u>	<u>1,376</u>	<u>24,049</u>

**3. Property, Plant and Equipment (Cont'd)**

The Company	Medical equipment \$'000	Furniture and fittings \$'000	Office equipment \$'000	Motor vehicles \$'000	Computers \$'000	Renovations \$'000	Total \$'000
<b>Cost</b>							
At 1 January 2003	1,179	1,416	620	501	1,782	1,875	7,373
Additions	41	68	33	-	91	351	584
Disposals	(309)	(289)	(84)	(24)	(85)	(1)	(792)
At 31 December 2003	<u>911</u>	<u>1,195</u>	<u>569</u>	<u>477</u>	<u>1,788</u>	<u>2,225</u>	<u>7,165</u>
<b>Accumulated depreciation</b>							
At 1 January 2003	819	761	286	184	1,124	1,046	4,220
Depreciation for the year	62	99	49	47	403	228	888
Disposals	(305)	(226)	(53)	(24)	(77)	-	(685)
At 31 December 2003	<u>576</u>	<u>634</u>	<u>282</u>	<u>207</u>	<u>1,450</u>	<u>1,274</u>	<u>4,423</u>
Depreciation charge for 2002	<u>65</u>	<u>119</u>	<u>57</u>	<u>40</u>	<u>398</u>	<u>239</u>	<u>918</u>
<b>Carrying amount</b>							
At 31 December 2003	<u>335</u>	<u>561</u>	<u>287</u>	<u>270</u>	<u>338</u>	<u>951</u>	<u>2,742</u>
At 31 December 2002	<u>360</u>	<u>655</u>	<u>334</u>	<u>317</u>	<u>658</u>	<u>829</u>	<u>3,153</u>

**3. Property, Plant and Equipment (Cont'd)**

Details of major leasehold properties of the Group are set out below:-

*Leasehold Properties*

Description/Location	Gross Floor Area (sq m)	Tenure	The Group Net Book Value	
			2003 \$'000	2002 \$'000
HDB shop with living quarters located at Blk 283 Bishan St 22 #01-177 Singapore 570283, held for use as a primary healthcare clinic	135.0	99 years commencing from 1/2/1991	1,098	1,124
A factory unit, located at 196 Pandan Loop #06-05 Pantech Industrial Complex, Singapore 128384, held for use as a store	112.0	99 years commencing from 27/1/1984	315	323
HDB shop unit, located at Blk 927 Yishun Central 1 #01-173 Singapore 760927, held for use as a primary healthcare clinic	76.0	99 years commencing from 1/9/1991	745	762
HDB shop with living quarters located at Blk 722 Ang Mo Kio Ave 8 #01-2825 Singapore 560722, held for use as a primary healthcare clinic	152.0	86 years commencing from 1/10/1993	1,528	1,564
HDB shop with living quarters located at Blk 131 Jurong East St 13 #01-267 Singapore 600131, held for use as a primary healthcare clinic	250.0	91 years commencing from 1/4/1993	1,907	1,950
HDB shop with living quarters located at Blk 177 Toa Payoh Central #01-170 Singapore 310177, held for use as a primary healthcare clinic	115.0	78 years commencing from 1/10/1992	1,191	1,217
HDB shop with living quarters located at Blk 479 Jurong West St 41 #01-266 Singapore 640479, held for use as a primary healthcare clinic	135.0	88 years commencing from 1/8/1995	637	650
HDB shop with living quarters located at Blk 203 Bedok North St 1 #01-467 Singapore 460203, held for use as a primary healthcare clinic	153.0	84 years commencing from 1/7/1992	942	963
			8,363	8,553

**3. Property, Plant and Equipment (cont'd)**

Valuation of the leasehold properties of a subsidiary were carried out in February 2002 by Jones Lang LaSalle Pte Ltd, a firm of independent valuers having appropriate professional qualifications, at open market values on an existing use basis.

**4. Interest in Subsidiaries**

	Company	
	2003 \$'000	2002 \$'000
(a) The interests in subsidiaries comprise:-		
Unquoted shares at cost	6,077	5,917
Amounts due from subsidiaries (mainly non-trade)	57,010	56,370
	63,087	62,287

The amounts due from subsidiaries are unsecured, interest-free and have no fixed terms of repayment. The management of the Company does not intend for the amounts to be repaid within the next twelve months.

(b) Details of investments in shares of subsidiaries are as follows:-

Name of Company	Effective Equity Interest held by the Company		Cost of Investment	
	2003 %	2002 &	2003 \$'000	2002 \$'000
Raffles Hospital Pte Ltd	100	100	2,257	2,257
Raffles Diagnostica Pte Ltd	100	100	1,733	1,733
Raffles Medical Properties Pte Ltd	100	100	1,227	1,227
Raffles International Medical Assistance Pte Ltd	100	100	200	200
Raffles Medical Management Pte Ltd	100	100	- *	- *
Raffles SurgiCentre Pte Ltd	100	100	- †	- †
Raffles Japanese Clinic Pte Ltd	80	-	160	-
Raffles Health Pte Ltd	100	-	- †	-
Aptitude [2003] Pte Ltd	100	-	- †	-
Raffles Medical International Pte Ltd and its subsidiary:	100	100	500	500
- Raffles Medical Group (Hong Kong) Limited and its subsidiary:	100	100	-	-
- Coors Consultants Limited	100	100	-	-
			6,077	5,917

\* denotes \$3

† denotes \$2

**4. Interest in Subsidiaries (cont'd)**

The principal activities and place of business and country of incorporation of the subsidiaries are as follows:-

<b>Name of Company</b>	<b>Principal Activities</b>	<b>Company</b>
* Raffles Hospital Pte Ltd	Provision of general and specialised medical services and operation of a hospital.	Singapore
* Raffles Diagnostica Pte Ltd	Operation of imaging centre and medical laboratories.	Singapore
* Raffles Medical Properties Pte Ltd	Investment holding.	Singapore
* Raffles International Medical Assistance Pte Ltd	Provision of medical evacuation and repatriation and provision of medical advisory services (currently dormant).	Singapore
* Raffles Medical Management Pte Ltd	Provision of business management and consultancy services (currently dormant).	Singapore
* Raffles SurgiCentre Pte Ltd	Provision of general and specialised medical services and operation of a hospital (currently dormant).	Singapore
* Raffles Japanese Clinic Pte Ltd	Operation of medical clinics and provision of medical services.	Singapore
* Raffles Health Pte Ltd	Trading in pharmaceutical and nutraceutical products and diagnostic equipment.	Singapore
* Aptitude [2003] Pte Ltd	Provision of advisory and consultancy services and developing IT solutions.	Singapore
* Raffles Medical International Pte Ltd	Investment holding.	Singapore
# Raffles Medical Group (Hong Kong) Limited	Operation of medical clinics and provision of medical and dental treatment services.	Hong Kong
# Coors Consultants Limited	Provision of management services to medical practitioners and the trading of medicine on an indent basis (currently dormant).	Hong Kong

\* Audited by KPMG Singapore

# Audited by Wong Brothers & Co., Hong Kong.

**5. Interest in Jointly Controlled Entities**

	Company	
	2003 \$'000	2002 \$'000
Investment at cost:-		
Ordinary shares	4,800	4,800
Redeemable preference shares	51,570	51,570
Share of post-acquisition losses	(5,785)	(6,775)
	50,585	49,595

Details of the jointly controlled entities are as follows:-

Name of Joint Venture Company	Principal Activities	Place of Incorporation and Business	Effective Equity held by the Group	
			2003	2002
Raffles Kaiser Permanente Healthcare Pte Ltd	Provision of healthcare consultancy services (Voluntarily liquidated by members in 2003)	Singapore	-	50%
* CapitaLand-Raffles Properties Pte Ltd	Property owner	Singapore	50%	50%
* Audited by KPMG Singapore				

The Group's share of CapitaLand-Raffles Properties Pte Ltd's results, assets and liabilities are as follows:

	2003 \$'000	2002 \$'000
<b>Results</b>		
Revenue	2,367	1,695
Expenses	(1,947)	(1,775)
	420	(80)
Profit/(Loss) before taxation	420	(80)
Taxation	570	-
	990	(80)
<b>Assets and liabilities</b>		
Non-current assets	95,570	95,000
Current assets	2,976	1,473
Current liabilities	(1,884)	(2,973)
Non-current liability	(46,077)	(43,905)
	(46,077)	(43,905)

**6. Unquoted Equity Investment**

	Group and Company	
	2003	2002
	\$'000	\$'000
Unquoted shares, at cost	700	700
Less:		
Write down of investment	(700)	(700)
	-	-

**7. Intangible Assets**

	Group and Company	
	2003	2002
	\$'000	\$'000
Assignment fees	690	690
Less:		
Disposal during the year	(78)	-
	612	690
Less:		
Amortisation:		
At 1 January	226	168
Disposal during the year	(31)	-
Amortisation charge for the year	57	58
At 31 December	252	226
	360	464

**8. Deferred Tax**

Movements in deferred tax assets and liabilities during the year are as follows:

	At 1 Jan 2003 \$'000	Charged/ (credited) to profit and loss account (note 24) \$'000	At 31 Dec 2003 \$'000
<b>Group</b>			
<b>Deferred tax liabilities</b>			
Property, plant and equipment	1,917	370	2,287
<b>Deferred tax assets</b>			
Unutilised tax losses carried forward	(1,587)	312	(1,275)
Unabsorbed wear and tear allowances	(1,313)	(308)	(1,621)
Other temporary differences	(360)	(70)	(430)
	<u>(3,260)</u>	<u>(66)</u>	<u>(3,326)</u>
<b>Company</b>			
<b>Deferred tax liabilities</b>			
Property, plant and equipment	443	(87)	356
<b>Deferred tax assets</b>			
Other temporary differences	(222)	(21)	(243)

Deferred tax liabilities and assets are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when the deferred taxes relate to the same taxation authority. The following amounts, determined after appropriate offsetting are as follows:

	Group		Company	
	2003 \$'000	2002 \$'000	2003 \$'000	2002 \$'000
Deferred tax liabilities	(767)	(681)	(113)	(221)
Deferred tax assets	1,806	2,024	-	-
	<u>1,039</u>	<u>1,343</u>	<u>(113)</u>	<u>(221)</u>

The following temporary differences have not been recognised:

	Group	
	2003 \$'000	2002 \$'000
Tax losses	<u>1,723</u>	<u>-</u>

Deferred tax assets have not been recognised in respect of these items because it is not probable that future taxable profits will be available against which the Group can utilise the benefits.

9. Investment in Commercial Notes

	Group and Company	
	2003 \$'000	2002 \$'000
<b>Current investment – market value</b>		
Investment in commercial notes	21,020	19,250

The investment in commercial notes have an effective interest rate of 1.34% (2002: 1.69%) and are repriceable every 3 months.

10. Trade and Other Receivables

	Note	Group		Company	
		2003 \$'000	2002 \$'000	2003 \$'000	2002 \$'000
Trade receivables	11	13,134	11,004	9,921	8,232
Deposits, prepayments and other receivables	12	2,281	1,963	1,335	1,208
Amounts due from:-					
Subsidiaries:					
- trade		-	-	7,673	9,902
- non-trade [see note (b) below]		-	-	3,216	5,576
Jointly controlled entity:					
- non-trade [see note (a) below]		-	75	-	-
Related parties:					
- trade		40	30	1	30
		<u>15,455</u>	<u>13,072</u>	<u>22,146</u>	<u>25,149</u>

(a) The amount due from a jointly controlled entity is unsecured, interest free and has no fixed terms of repayment.

(b) Amount due from subsidiaries:-					
non-trade		-	-	5,316	5,776
Less:					
Allowance for doubtful receivables		-	-	(2,100)	-
Net receivables		<u>-</u>	<u>-</u>	<u>3,216</u>	<u>5,776</u>

**11. Trade Receivables**

	Group		Company	
	2003 \$'000	2002 \$'000	2003 \$'000	2002 \$'000
Trade receivables	15,067	12,650	11,129	9,319
Less:				
Allowance for doubtful receivables	(1,933)	(1,646)	(1,208)	(1,087)
	<u>13,134</u>	<u>11,004</u>	<u>9,921</u>	<u>8,232</u>

**12. Deposits, Prepayment and Other Receivables**

	Group		Company	
	2003 \$'000	2002 \$'000	2003 \$'000	2002 \$'000
Deposits	957	1,037	498	619
Prepayments	529	213	294	108
Non-trade receivables	263	143	72	87
Loans to directors (see note below)				
- Directors of subsidiaries	372	83	329	-
Staff loan	160	487	142	394
	<u>2,281</u>	<u>1,963</u>	<u>1,335</u>	<u>1,208</u>

The loans to directors were granted in accordance with the Group's Loan Scheme for Executive Directors, approved by the shareholders at an Extraordinary General Meeting held on 29 October 1997.

**13. Cash and Cash Equivalents**

	Group		Company	
	2003 \$'000	2002 \$'000	2003 \$'000	2002 \$'000
Fixed deposits	9,600	7,500	9,600	7,500
Cash and bank balances	1,711	1,430	430	367
	<u>11,311</u>	<u>8,930</u>	<u>10,030</u>	<u>7,867</u>
Bank overdraft (unsecured)	(662)	(172)	-	-
	<u>10,649</u>	<u>8,758</u>	<u>10,030</u>	<u>7,867</u>

The fixed deposits have an effective interest rate of 0.5% (2002: 0.65%) per annum.

The bank overdraft has an effective interest rate of 5.87% (2002: 6.26%) per annum.

**14. Trade and Other Payables**

	Note	2003 \$'000	Group 2002 \$'000	2003 \$'000	Company 2002 \$'000
Trade payables		8,715	6,132	3,450	2,216
Other payables and accruals	15	11,349	11,590	6,880	6,575
Amounts due to:-					
Subsidiaries:					
- trade		-	-	276	138
- non-trade	16	-	-	715	714
Related parties:					
- trade		45	45	45	45
		<u>20,109</u>	<u>17,767</u>	<u>11,366</u>	<u>9,688</u>

**15. Other Payables and Accruals**

	2003 \$'000	Group 2002 \$'000	2003 \$'000	Company 2002 \$'000
Accrued operating expenses	10,092	10,437	6,789	6,488
Other payables	1,257	1,153	91	87
	<u>11,349</u>	<u>11,590</u>	<u>6,880</u>	<u>6,575</u>

**16. Amounts due to Subsidiaries (Non-Trade)**

The non-trade amounts due to subsidiaries are unsecured, interest-free and have no fixed terms of repayment.

**17. Deferred Income**

	2003 \$'000	Group 2002 \$'000	2003 \$'000	Company 2002 \$'000
At 1 January	595	2,006	539	1,948
Amount received/receivable during the year	1,769	8,348	1,529	8,095
Amount recognised as income during the year	(2,204)	(9,759)	(1,963)	(9,504)
At 31 December	<u>160</u>	<u>595</u>	<u>105</u>	<u>539</u>

**18. Interest-Bearing Loans and Borrowings (Unsecured)**

	Group and Company	
	2003 \$'000	2002 \$'000
Repayable within 12 months	1,997	2,093

The interest bearing loans have an effective interest rate of 3.1% per annum (2002: 3.53% per annum.)

**19. Employee Benefits**

	Group		Company	
	2003 \$'000	2002 \$'000	2003 \$'000	2002 \$'000
Defined contribution plan	2,185	1,961	1,120	894
Liability for short-term accumulating compensated absences	870	599	568	423
	<u>3,055</u>	<u>2,560</u>	<u>1,688</u>	<u>1,317</u>

## Equity compensation benefits

The Raffles Medical Group Employees' Share Option Scheme ("RMG 1997 Scheme") for the Company which was approved and adopted in 1997 was terminated on 31 October 2000. The termination of the RMG 1997 Scheme will not affect the subscription rights comprised in options granted pursuant to the RMG 1997 Scheme prior to the termination. Such options will continue to be exercisable in accordance with the rules of the RMG 1997 Scheme. On 31 October 2000, the shareholders of the Company approved the Raffles Medical Group (2000) Share Option Scheme ("RMG 2000 Scheme") at the Extraordinary General Meeting. Both the Schemes are administered by the Committee comprising three directors, Dr Loo Choon Yong, Prof Lim Pin and Assoc Prof Wee Beng Geok.

Other statutory information regarding the Schemes are set out below:-

## RMG 1997 Scheme

- (i) The exercise price of the options is determined at the average closing price of the Company's shares on the Singapore Exchange Securities Trading Limited on the three business days immediately preceding the date of grant of such options.
- (ii) The options vest 1 year after the grant date.
- (iii) The options granted expire after 5 years from the grant date unless they are cancelled or have lapsed.

**19. Employee Benefits (Cont'd)**

RMG 2000 Scheme

(i) Subscription price:

(a) The exercise price of the options is determined at the average closing price of the Company's shares on the Singapore Exchange Securities Trading Limited on the three business days immediately preceding the date of grant of such options, or

(b) the discounted value of the share price determined under (a) above, provided that the maximum discount shall not exceed 20% of (a) above.

(ii) The options vest on such date in respect of such proportion of the option amount as the Committee may prescribe but shall be no earlier than 1 year after the grant date for (i)(a) and 2 years after the grant date for (i)(b).

(iii) The options granted expire after 10 years for employees and 5 years for non-employees from the grant date unless they are cancelled or have lapsed.

Equity compensation benefits (cont'd)

As at the end of the financial year, details of the options granted under the Scheme on the unissued ordinary shares of \$0.10 each of the Company were as follows:-

Movements of share options granted:-

Date of grant of options	Exercise price	Number of options outstanding 1 Jan 2002	Options Granted	Options exercised	Options cancelled/lapsed	Number of options outstanding 31 Dec 2002	Proceeds on options exercise Credited to share capital	Credited to share premium	Market price of shares at date of issue pursuant to the Scheme	Exercisable period
18/5/1998	\$0.540	2,171,100	-	-	(2,171,100)	-	-	-	\$0.63 to \$0.64	18/5/99 to 17/5/03
9/3/2000	\$0.570	5,400,600	-	-	(309,100)	5,091,500	-	-	\$0.67 to \$0.68	9/3/01 to 8/3/05
15/2/2001	\$0.430	9,013,000	-	-	(1,267,000)	7,746,000	-	-	\$0.44	15/2/02 to 14/2/11
15/2/2001	\$0.430	610,000	-	-	-	610,000	-	-	\$0.44	15/2/03 to 14/2/11
15/2/2001	\$0.430	500,000	-	-	-	500,000	-	-	\$0.44	15/2/02 to 14/2/06
15/2/2001	\$0.430	50,000	-	-	-	50,000	-	-	\$0.44	15/2/03 to 14/2/06
8/4/2002	\$0.330	9,070,000	-	(724,000)	(753,000)	7,593,000	72,400	166,520	\$0.34	8/4/03 to 7/4/12
8/4/2002	\$0.330	1,726,000	-	-	(20,000)	1,706,000	-	-	\$0.34	8/4/04 to 7/4/12
8/4/2002	\$0.330	1,258,000	-	-	-	1,258,000	-	-	\$0.34	8/4/05 to 7/4/12
8/4/2002	\$0.330	680,000	-	-	(85,000)	595,000	-	-	\$0.34	8/4/03 to 7/4/07
8/4/2002	\$0.330	420,000	-	-	-	420,000	-	-	\$0.34	8/4/04 to 7/4/07
8/4/2002	\$0.330	120,000	-	-	-	120,000	-	-	\$0.34	8/4/05 to 7/4/07
31/3/2003	\$0.285	-	7,363,000	-	(770,000)	6,593,000	-	-	\$0.285	31/3/04 to 30/3/13
31/3/2003	\$0.285	-	1,100,000	-	-	1,100,000	-	-	\$0.285	31/3/05 to 30/3/13
31/3/2003	\$0.285	-	260,000	-	-	260,000	-	-	\$0.285	31/3/06 to 30/3/13
31/3/2003	\$0.285	-	755,000	-	(65,000)	690,000	-	-	\$0.285	31/3/04 to 30/3/08
31/3/2003	\$0.285	-	400,000	-	-	400,000	-	-	\$0.285	31/3/05 to 30/3/08
31/3/2003	\$0.285	-	-	-	-	-	-	-	\$0.285	31/3/06 to 30/3/08
			<u>31,018,700</u>	<u>9,878,000</u>	<u>(724,000)</u>	<u>(5,440,200)</u>	<u>34,732,500</u>	<u>72,400</u>	<u>166,520</u>	

**19. Employee Benefits (Cont'd)**

Equity compensation benefits (Cont'd)

Movements of share options vested:-

Date of grant of options	Number of options vested 1 Jan 2002	Number of options vested in 2002	Number of options exercised in 2002	Number of options cancelled/lapsed in 2002	Number of options vested 31 Dec 2002	Exercisable period
18/5/1998	2,207,000	-	-	(35,900)	2,171,100	18/5/99 to 17/5/03
9/3/2000	5,473,600	-	-	(73,000)	5,400,600	9/3/01 to 8/3/05
15/2/2001	-	9,519,000	-	(506,000)	9,013,000	15/2/02 to 14/2/11
15/2/2001	-	500,000	-	-	500,000	15/2/02 to 14/2/06
	<u>7,680,600</u>	<u>10,019,000</u>	<u>-</u>	<u>(614,900)</u>	<u>17,084,700</u>	

**20. Share Capital**

	Company	
	2003 \$'000	2002 \$'000
Authorised:		
500,000,000 ordinary shares of \$0.10 each	<u>50,000</u>	<u>50,000</u>
Issued and Paid-up Capital:		
387,343,999 (2002: 386,619,999) ordinary shares of \$0.10 each fully paid	<u>38,734</u>	<u>38,662</u>

Unissued ordinary shares of \$0.10 each of the Company under options granted to eligible directors and employees under the Company's Employees' Share Option Schemes are disclosed in Note 19.

**21. Reserves**

	Group		Company	
	2003 \$'000	2002 \$'000	2003 \$'000	2002 \$'000
Share premium	53,157	52,990	53,157	52,990
Exchange translation reserve	(173)	(269)	-	-
Accumulated profits	<u>4,574</u>	<u>2,545</u>	<u>10,859</u>	<u>11,854</u>
	<u>57,558</u>	<u>55,266</u>	<u>64,016</u>	<u>64,844</u>

The application of the share premium account is governed by Sections 69-69F of the Singapore Companies Act, Chapter 50.

The exchange translation reserve of the Group comprises all foreign exchange differences arising from the translation of the financial statements of foreign subsidiaries.

**22. Revenue**

Revenue for the Group represents fees invoiced and earned in respect of services provided to third parties after eliminating inter-company transactions.

**23. Profit from Operations**

The following items have been included in arriving at profit from operations:-

	Note	2003 \$'000	Group 2002 \$'000
<b>(a) Other income</b>			
Interest income from fixed deposits and commercial notes		<u>308</u>	<u>298</u>
<b>(b) Inventories and consumables used</b>			
Inventories written off		613	-
Other inventories and consumables used		11,522	9,059
		<u>12,135</u>	<u>9,059</u>
<b>(c) Staff costs</b>			
Wages and salaries		51,689	45,518
Contributions to defined contribution plans		4,788	4,226
Increase in liability for short-term accumulating compensated absences	19	271	256
		<u>56,748</u>	<u>50,000</u>
Number of employees as at 31 December		<u>1,160</u>	<u>918</u>

**23. Profit from Operations (cont'd)**

	2003 \$'000	Group	2002 \$'000
<b>(d) Other operating expenses</b>			
Allowance for doubtful trade receivables (net)	534		290
Foreign exchange loss	9		330
Non-audit fees paid to auditors of the Company	14		17
Property, plant and equipment written off	365		293
Loss on disposal of intangible assets	29		-
Rental expenses	7,447		6,770
Bad debts written off	67		49
Others	8,847		11,834
	<u>17,312</u>		<u>19,583</u>
<b>(e) Directors' remuneration</b>			
Directors' remuneration is recognised in the following line items in the profit and loss accounts:-			
Staff costs:-			
directors of the Company	1,834		1,154
directors of the subsidiaries	3,254		2,320
Other operating expenses:-			
directors of the Company	110		70
directors of the subsidiaries	20		20
	<u>5,218</u>		<u>3,564</u>
<b>(f) Finance costs</b>			
Interest paid and payable on:-			
Bank loans	62		36
Bank overdrafts	29		57
	<u>91</u>		<u>93</u>

24. Income Taxes

	2003 \$'000	Group	2002 \$'000
<b>Current tax expense</b>			
Current year	2,453		1,842
Under/(Over) provision in prior years	13		(35)
	<u>2,466</u>		<u>1,807</u>
<b>Deferred tax expense</b>			
Movements in temporary differences	(101)		(259)
Reversal of deferred tax asset	405		-
Reduction in tax rate	-		48
	<u>2,770</u>		<u>1,596</u>
Share of tax of jointly controlled entity	(570)		-
Income tax expense	<u>2,200</u>		<u>1,596</u>
<b>Reconciliation of effective tax rate</b>			
<b>Group</b>			
Profit from ordinary activities before taxation	<u>10,208</u>		<u>6,102</u>
Income tax using Singapore corporate tax rate of 22% (2002: 22%)	2,245		1,342
Effect of different tax rates in other countries	27		84
Effect of reduction in tax rate on temporary differences	-		48
Expenses not deductible for tax purposes	222		100
Utilisation of previously unrecognised deferred tax assets	(186)		-
Under provision of income tax in respect of prior years	13		(35)
Reversal of deferred tax in respect of jointly controlled entity	(570)		-
Reversal of deferred tax in respect of prior years	405		-
Others	44		57
	<u>2,200</u>		<u>1,596</u>

**25. Earning Per Share**

The basic earnings per share is based on consolidated profit after tax of \$8,060,000 (2002: \$4,506,000) and weighted average of 386,875,556 (2002: 386,619,999) shares.

When calculating the diluted earnings per share, the weighted average number of shares is adjusted for the effect of all dilutive potential shares. The adjusted weighted average number of shares is as follows:-

	2003 \$'000	2002 \$'000
Weighted average number of shares used in calculation of basic earnings per share	386,876	386,620
Weighted average number of shares under options that would have been issued at fair value	2,733	-
Weighted average number of shares used in calculation of diluted earnings per share	389,609	386,620

**26. Commitments****(a) Operating lease commitments**

At 31 December 2003, the Group and the Company have commitments for future minimum lease payments under non-cancellable operating leases as follows:-

	Group		Company	
	2003 \$'000	2002 \$'000	2003 \$'000	2002 \$'000
Payable:-				
Within 1 year	9,782	6,539	3,872	1,874
After 1 year but within 5 years	19,822	21,042	5,504	2,164

The leases typically run for an initial period of three to six years, with an option to renew the lease after that date. For renewed leases, the lease payments are determined based on the prevailing market rent at the point of renewal.

In addition, contingent rent payments are determined as a percentage of bed sales each month.

**26. Commitments (cont'd)**

**(b) Sub-lease receivables**

At 31 December 2003, the Group has future minimum sub-lease income under non-cancellable operating leases with terms more than one year as follows:

	2003 \$'000	Group	2002 \$'000
Receivable:-			
Within 1 year	1,006		955
After 1 year but within 5 years	413		579
	<u>1,419</u>		<u>1,534</u>

Contingent rental income consists of a turnover fee, calculated as the amount in excess of a certain threshold of the tenants monthly revenue.

**(c) Proposed dividends**

After the balance sheet date, the Directors proposed the following dividends. These dividends have not been provided for:-

	2003 \$'000	2002 \$'000
Final and special dividends proposed of 1.5 cents and 1 cent (2002: 1 cent and 1 cent respectively) respectively per share less tax at 20% (2002: 22%)	<u>7,747</u>	<u>6,031</u>

**27. Significant Related Parties Transactions**

For the purpose of these financial statements, parties are considered to be related to the Group if the Group has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Group and the party are subject to common control or common significant influence. Related parties may be individuals or other entities.

During the year, there were no significant related party transactions carried out on terms agreed between the parties:-

	2003 \$'000	Group	2002 \$'000
Rental expenses paid to a company in which a director has a substantial interest	<u>-</u>		<u>95</u>

**28. Financial Instruments****(a) Financial risk management objectives and policies**

The Group is exposed to credit risk, interest rate risk and foreign currency risk which arises in the normal course of the Group's business. The Group has risk management policies and guidelines which set out its overall business strategies, its tolerance for risk and its general risk management philosophy.

**(b) Credit risk**

Management has a credit policy in place and the exposure to credit risk is monitored on an ongoing basis. Credit evaluations are performed on customers requiring credit over the recommended limit set by management.

**(c) Interest rate risk**

The Group's exposure to interest rate risk relates primarily to bank facilities and commercial papers with financial institutions.

**(d) Foreign currency risk**

In respect of other monetary assets and liabilities held in currencies other than in Singapore dollars, the Group ensures that the net exposure to currency fluctuation is kept to an acceptable level.

**(e) Fair value***Recognised financial instruments*

The face value less any estimated credit adjustments for financial assets and liabilities with a maturity of less than one year (including trade and other receivables, cash and cash equivalents and trade and other payables, bank overdrafts, and interest bearing loans and borrowings) are assumed to approximate their fair values.

The market values of investment in commercial notes as disclosed in Note 9 represent their fair value.

It is not practical to estimate the fair values of unquoted investments because of a lack of quoted market prices and the difficulty of obtaining a reliable or similar financial instrument for any comparison or estimation to be made. Management believes that the carrying amounts recorded at balance sheet date reflect the corresponding fair value.

**29. Contingent Liabilities (Secured)**

As at 31 December 2003, the Company has given to banks guarantees (secured) amounting to \$46,827,000 (2002: \$43,905,000) in respect of credit facilities extended to its subsidiaries and a jointly controlled entity.

**30. Change in Accounting Policies**

For the financial year ended 31 December 2003, the operation of the medical laboratory and imaging centre previously reported under "Diagnostics" segment has been expanded. The new expanded segment is called "Hospital services".

The provision of specialised medical services and the operation of hospital previously reported as part of the "Healthcare" segment are now reported under the new "Hospital services" segment.

The change was made as the Board of Directors are of the view that it is a better reflection of the operations of the Group and more meaningful for users of the financial statements.

The comparative figures have been adjusted to take into account of the change.

### 31. Segment Reporting

Segment information is presented in respect of the Group's business and geographical segments. The primary format, business segments, is based on the Group's management and internal reporting structure.

Inter-segment pricing is determined on an arm's length basis.

Segment results, assets and liabilities include items directly attributable to a segment as well as those that can be allocated on a reasonable basis.

Segment capital expenditure is the total cost incurred during the period to acquire segment assets that are expected to be used for more than one period.

#### **Business Segments**

The Group comprises the following main business segments:-

Healthcare services : The operations of medical clinics and other general medical services; trading in pharmaceutical and nutraceutical products and diagnostic equipment; and provision of management and consultancy services.

Hospital services : The provision of specialised medical services and operation of hospital and business of medical laboratory and imaging centre.

Investment holdings : The investment in a jointly controlled entity and investment holding.

In presenting information on the basis of geographical segments, segment revenue is based on the geographical location of the customers. Segment assets are based on the geographical location of the assets.

#### **(a) Business Segments**

	Health services \$'000	Hospital services \$'000	Investment holdings \$'000	Eliminations \$'000	Consolidated \$'000
<b>2003</b>					
<b>Revenue and expenses</b>					
Total revenue from					
external customers	61,486	37,518	101	-	99,105
Inter-segment revenue	17	3,016	506	(3,539)	-
Segment results	<u>61,503</u>	<u>40,534</u>	<u>607</u>	<u>(3,539)</u>	<u>99,105</u>
	<u>8,241</u>	<u>1,360</u>	<u>278</u>	<u>-</u>	<u>9,879</u>
Finance costs					(91)
Share of profit in a jointly controlled entity	-	-	420	-	420
Income tax expense					(2,200)
Minority interests					52
Net profit for the year					<u>8,060</u>

31. Segment Reporting (cont'd)  
(a) Business Segments (cont'd)

	Health services \$'000	Hospital services \$'000	Investment holdings \$'000	Eliminations \$'000	Consolidated \$'000
<b>2003</b>					
<b>Other segmental information</b>					
Capital expenditure	951	996	-	(53)	1,894
Depreciation expense	1,116	1,975	191	-	3,282
Amortisation expense	-	-	57	-	57
Other non-cash expenses	548	332	48	-	928
<b>2002</b>					
<b>Revenue and expenses</b>					
Total revenue from external customers	55,205	32,706	86	-	87,997
Inter-segment revenue	-	4,155	506	(4,661)	-
	55,205	36,861	592	(4,661)	87,997
Segment results	5,227	757	291	-	6,275
Finance costs					(93)
Share of loss in a jointly controlled entity	-	-	(80)	-	(80)
Income tax expense					(1,596)
Net profit for the year					4,506
<b>Other segmental information</b>					
Capital expenditure	1,288	2,005	-	-	3,293
Depreciation expense	1,133	1,997	190	-	3,320
Amortisation expense	-	-	58	-	58
Other non-cash expenses	786	(203)	-	-	583

31. Segment Reporting (cont'd)  
(a) Business Segments (cont'd)

	Health services \$'000	Hospital services \$'000	Investment holdings \$'000	Eliminations \$'000	Consolidated \$'000
<b>2003</b>					
<b>Assets and Liabilities</b>					
Segment assets	122,628	25,120	8,734	(83,128)	73,354
Interest in jointly controlled entity	-	-	50,585	-	50,585
Deferred tax assets					1,806
Total assets					<u>125,745</u>
Segment liabilities	24,165	17,154	63,976	(79,312)	25,983
Current and deferred tax liabilities					3,322
Total liabilities					<u>29,305</u>
<b>2002</b>					
<b>Assets and Liabilities</b>					
Segment assets	120,463	26,432	9,038	(87,844)	68,089
Interest in jointly controlled entity	-	-	49,595	-	49,595
Deferred tax assets					2,024
Total assets					<u>119,708</u>
Segment liabilities	20,982	19,682	64,451	(81,928)	23,187
Current and deferred tax liabilities					2,593
Total liabilities					<u>25,780</u>

**31. Segment Reporting (cont'd)**  
*(b) Geographical Segments*

	Singapore \$'000	Hong Kong \$'000	Consolidated \$'000
<b>2003</b>			
Total revenue from external customers	95,408	3,697	99,105
Segment assets	71,826	1,528	73,354
Capital expenditure	1,779	115	1,894
<b>2002</b>			
Total revenue from external customers	84,372	3,625	87,997
Segment assets	66,584	1,505	68,089
Capital expenditure	3,232	61	3,293

**32. Comparative Information**

Comparatives in the financial statements have been changed from the previous year due to changes in accounting policies as described in note 30.

## Additional Information

Year ended 31 December 2003

### 1. Directors' Remuneration

The following information relates to remuneration of directors of Raffles Medical Group Ltd:-

Remuneration Bands	Number of Directors	
	2003	2002
\$500,000 and above	1	1
\$250,000 - \$499,999	-	-
Below \$250,000	4	4
	5	5

## Shareholding Statistics

as at 10 March 2004

### Share Capital

Authorised share capital	-	S\$50,000,000
Issued and fully paid-up	-	S\$38,759,599,90
Class of shares	-	Ordinary shares of S\$0.10 each
Voting rights	-	1 vote per ordinary share

### Shareholdings Held in Hands of Public

Based on information available to the Company as at 10 March 2004, approximately 34.45% of the issued ordinary shares of the Company is held by the public and therefore Rule 723 of the Listing Manual is complied with.

### Analysis Of Shareholdings

Range of Shareholdings	No. of Shareholders	%	No. of Shares	%
1 - 999	41	0.44	17,060	0.00
1,000 - 10,000	7,396	79.76	28,867,090	7.45
10,001 - 1,000,000	1,816	19.58	60,383,050	15.58
1,000,001 and above	20	0.22	298,328,799	76.97
	<u>9,273</u>	<u>100.00</u>	<u>87,595,999</u>	<u>100.00</u>

### Substantial Shareholders

Name	Direct Interest	%	Deemed Interest	%
Dr Loo Choon Yong	31,841,999	8.22	222,157,000	57.32
Raffles Medical Holdings Pte Ltd	205,907,000	53.12	-	-

### Top 20 Shareholders as at 10 March 2004

No.	Name	No. of Shares	%
1	Overseas Union Bank Nominees Pte Ltd	80,000,000	20.64
2	Raffles Medical Holdings Pte Ltd	78,390,000	20.22
3	DBS Nominees Pte Ltd	58,268,400	15.03
4	Loo Choon Yong	24,892,999	6.42
5	Lu Qing Hui	16,000,000	4.13
6	United Overseas Bank Nominees Pte Ltd	11,595,200	2.99
7	Oversea Chinese Bank Nominees Pte Ltd	4,472,400	1.15
8	HL Bank Nominees (S) Pte Ltd	4,088,000	1.05
9	UOB Kay Hian Pte Ltd	2,509,200	0.65
10	Hong Leong Finance Nominees Pte Ltd	2,329,100	0.60
11	Yii Hee Seng	2,037,000	0.53
12	Tan Tiang Lee	2,000,000	0.52
13	SBS Nominees Pte Ltd	1,962,500	0.51
14	Yang Ching Yu	1,560,000	0.40
15	Kim Eng Securities Pte Ltd	1,554,000	0.40
16	Kwok Wai Ling	1,542,000	0.40
17	Goh Ah Hoe	1,457,000	0.38
18	ING Nominees (S'pore) Nominees Pte Ltd	1,310,000	0.34
19	Shek Chee Keong	1,266,000	0.33
20	Teh Lim Song	1,095,000	0.28
		<u>298,328,799</u>	<u>76.97</u>

## Notice of Annual General Meeting

NOTICE IS HEREBY GIVEN that the 15th Annual General Meeting of the Company will be held at 585 North Bridge Road, Raffles Hospital #11-00, Singapore 188770 on Friday, 23 April 2004 at 3.00 pm to transact the following business:

### AS ORDINARY BUSINESS

1. To receive and adopt the Directors' Report and Accounts and the Auditors' Report thereon for the year ended 31 December 2003. **(Resolution 1)**
2. To approve the payment of a first and final dividend of 15% less tax for the year ended 31 December 2003. **(Resolution 2)**
3. To approve the payment of a special dividend of 10% less tax for the year ended 31 December 2003. **(Resolution 3)**
4. To approve Directors' fees (\$110,000) for the year ended 31 December 2003 (2002: \$70,000). **(Resolution 4)**
5. To re-elect the following Director who is retiring under Article 97 of the Articles of Association of the Company:
  - 5.1 Prof Lim Pin  
subject to his re-election, Prof Lim Pin who is an Independent Director for the purpose of Clause 704 (8) of the Listing Manual of the Singapore Exchange will be reappointed as Member of the Nomination & Compensation Committee. **(Resolution 5)**
6. To re-appoint KPMG as Auditors and authorise Directors to fix their remuneration. **(Resolution 6)**

### AS SPECIAL BUSINESS

7. To consider and, if thought fit, pass the following Ordinary Resolutions:  
RESOLVED that:

the Directors be and hereby authorised pursuant to the provisions of Section 161 of the Companies Act, Cap. 50 to allot and issue such of the unissued shares of the Company on such terms and conditions and with such rights or restrictions as they may deem fit PROVIDED ALWAYS THAT:

- (i) the aggregate number of shares to be issued pursuant to this Resolution does not exceed fifty percent (50%) of the issued share capital of the Company, for the time being and
- (ii) the aggregate number of shares issued other than on a pro-rata basis to the existing shareholders does not exceed twenty percent (20%) of the issued share capital of the Company for the time being and

that such authority shall continue in force until the conclusion of the next Annual General Meeting or the expiration of the period within which the next Annual General Meeting of the Company is required by law to be held, whichever is the earlier.

**(Resolution 7)**

**AS SPECIAL BUSINESS (cont'd)**

8. the Directors of the Company be and are hereby authorised to offer and grant options in accordance with the provisions of the Raffles Medical Group (2000) Share Option Scheme (the "Scheme") and to allot and issue from time to time such number of shares in the capital of the Company as may be required to be issued pursuant to the exercise of such options under the Scheme, provided that the aggregate number of shares to be issued pursuant to the Scheme shall not exceed 15 percent of the total issued share capital of the Company from time to time.

**(Resolution 8)**

9. To transact any other business which may be properly transacted at an Annual General Meeting.

NOTICE IS ALSO HEREBY GIVEN that the Transfer Books and Register of Members of the Company will be closed on 2nd May 2004, for the preparation of dividend warrants. Duly completed transfers received by the Company's Register, M&C Services Private Limited, 138 Robinson Road, #17-00 The Corporate Office, Singapore 068906, up to the close of the business at 5.00 p.m. on 30th April 2004 be registered to determine shareholders' entitlement to the proposed dividend. The proposed first and final dividend and the special dividend if approved at the Annual General Meeting will be paid on 12 May 2004.

BY ORDER OF THE BOARD

**Moiz Tyebally**  
**Company Secretary**  
**Singapore, 7 April 2004**

**Notes:**

An ordinary shareholder entitled to attend and vote at the Meeting is entitled to appoint a proxy to attend and to vote in his stead. An ordinary shareholder of the Company which is a corporation is entitled to appoint its authorised representative or proxy to vote on its behalf.

A proxy need not be a member of the Company.

The instrument appointing a proxy must be deposited at the Company's Office at 585 North Bridge Road, Raffles Hospital #11-00, Singapore 188770, at least 48 hours before the time for holding the Meeting.

# Proxy Form

**Important**

- For investors who have used their CPF monies to buy Raffles Medical Group Ltd shares, Annual Report is forwarded to them at the request of their CPF Approved Nominee and is sent solely FOR INFORMATION ONLY.
- This Proxy Form is not valid for use by CPF Investors and shall be ineffective for all intents and purposes if used or purported to be used by them.

I/We \_\_\_\_\_

of \_\_\_\_\_

being a member/member of the abovementioned Company hereby appoint

Name	Address	NRIC/Passport Number	Proportion of Shareholdings (%)

Add/or (delete as appropriate)

--	--	--	--

as my/our proxy/proxies to attend and to vote for me/us on my/our behalf, and if necessary, to demand a poll, at the Annual General Meeting of the Company to be held on Friday, 23 April 2004 at 300 pm and at any adjournment thereof.

(Please indicate with an "X" in the spaces provided whether you wish to vote (s) to be cast for or against the Ordinary Resolutions as set out in the Notice of Annual General Meeting. In the absence of specific directions, the proxy/proxies will vote or abstain as he/they may think fit, as he/they will on any other matters arising at the Annual General Meeting).

No.		For	Against
<b>ORDINARY BUSINESS</b>			
1	Adoption of Report and Accounts (Resolution 1)		
2	Declaration of Dividend (Resolution 2)		
3	Declaration of Special Dividend (Resolution 3)		
4	Approval of Directors' Fee (Resolution 4)		
5	Re-election of the following Directors in accordance with Article 97 of the Articles of Association of Company		
	5.1 Prof Lim Pin (Resolution 5)		
6	Re-appointment of KPMG as Auditors (Resolution 6)		
<b>SPECIAL BUSINESS</b>			
7	Authority to issue shares up to 50% of issued capital (Resolution 7)		
8	Authority to offer Raffles Medical Group (2000) Share Option Scheme (Resolution 8)		

Dated this \_\_\_\_\_ day of \_\_\_\_\_ 2003

Total Number of Shares Held

---

\_\_\_\_\_  
Signature(s) of Member(s) or Common Seal

Fold this Flap For Sealing

Please  
Affix  
Stamp  
Here

The Company Secretary  
Raffles Medical Group Ltd  
585 North Bridge Road  
#11-00 Raffles Hospital  
Singapore 188770

2nd Fold Here

Notes To Proxy Form:

A member of the Company entitled to attend and vote at the Annual General Meeting is entitled to appoint not more than two proxies to attend and vote in his stead. Such proxy need not be a member of the Company. Where a member appoints two proxies, the appointments shall be invalid unless he specifies the proportion of his shareholding (expressed as a percentage of the whole) to be represented by each proxy.

The instrument appointing a proxy or proxies (together with the power of attorney, if any, under which it is signed or a notarially certified copy thereof) must be deposited at the registered office of the Company at 585 North Bridge Road, #11-00 Raffles Hospital, Singapore 188770 not later than 48 hours before the time appointed for the Annual General Meeting.

A corporation which is a member may authorise by a resolution of its directors or other governing body such person as it thinks fit to act as its representative at the 15th Annual General Meeting, in accordance with Section 161 of the Companies Act, Cap. 50 of Singapore.

3rd Fold Here

Please inset the total number of shares held by you. If you have shares entered against your name in the Depository Register (as defined in Section 130A of the Companies Act, Cap. 50 of Singapore), you should insert that number of shares. If you have share registered in your name in the Register of Members, you should insert the number of shares. If you have shares entered against your name in the Depository Register and shares registered in your name in the Register of Members, you should insert the aggregate number of shares entered against your name in the Depository Register and registered in your name in the Register of Members.

The Company shall be entitled to reject the instrument appointing a proxy or proxies if it is incomplete, improperly completed or illegible or where the true intentions of the appointor are not ascertainable from the instructions of the appointor specific in the instrument appointing a proxy or proxies. In addition, in the case of members whose shares are entered in the Depository Register, the Company may reject any instrument appointing a proxy or proxies lodged if such members are not shown to have shares entered against their names in the Depository Register as at 48 hours before the time appointed for holding the Annual General Meeting, as certified by The Central Depository (Pte) Limited ("CDP") to the Company.